Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  panitumumab
Find trials that include:  Any drugs shown
Results 1-18 of 18 for your search:
Start Over
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CMEK162X2116, NCI-2014-00903, 2013-001986-18, NCT01927341
Irinotecan Hydrochloride and Panitumumab as Second-Line Therapy in Treating Patients With Locally Recurrent or Metastatic Esophageal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: 07-161, NCI-2011-02478, NCT00836277
Erlotinib Hydrochloride and Panitumumab with or without Irinotecan Hydrochloride as Second Line Therapy in Patients with Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 07I4, NCI-2011-00222, OSI 4263s, NCT00940316
Chemotherapy and Radiation Therapy with or without Panitumumab in Treating Patients with Stage IIIA Non-Small Cell Lung Cancer (Cetuximab Closed as of 05/14/10)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 0839, NCI-2011-01970, CDR0000654690, NCT00979212
Panitumumab, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, and Carboplatin in Treating Patients with HER2-Negative Primary Inflammatory Breast Cancer Receiving Combination Chemotherapy and Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2008-0372, NCI-2012-00935, NCI-2010-02235, NCT01036087
Panitumumab in Treating Patients with Locally Advanced or Metastatic Small Intestine or Ampulla of Vater Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2009-0458, NCI-2012-01894, NCI-2010-02085, NCT01202409
Panitumumab, Combination Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Advanced Esophageal or Gastroesophageal Junction Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 221-09, NCI-2010-02056, NCT01307956
Combination Chemotherapy with or without Panitumumab in Treating Patients with Colorectal Cancer with Liver Metastases Previously Treated with Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-137, NCI-2011-00375, NCT01312857
BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116833, NCI-2014-00142, NCT01750918
A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI608-224, NCI-2014-01095, NCT01776307
Panitumumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Combination Chemotherapy and Bevacizumab
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: OSU-11131, NCI-2013-00432, 2012C0033, NCT01814501
Gemcitabine Hydrochloride, Carboplatin, and Panitumumab before Surgery in Treating Patients with Bladder Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-103, NCI-2013-01611, NCT01916109
Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 391401, NCI-2015-01016, 2015-000896-28, NCT02448810
Everolimus in Combination With Fluorouracil, Leucovorin Calcium, Panitumumab, and Oxaliplatin in Treating Patients With Refractory Solid Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LCCC 0621, NCI-2013-00941, UNC-LCCC-0621, NCT00610948
Panitumumab Pediatric Study
Phase: Phase I
Type: Treatment
Age: 1 to 17
Trial IDs: 20050252, NCI-2010-01498, NCT00658658
Ganitumab, Everolimus, and Panitumumab in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: Pro00021317, NCI-2013-02192, NCT01061788
Cabozantinib-S-Malate and Panitumumab in Treating Patients with Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049983, NCI-2014-01160, NCT02008383
Regorafenib and Panitumumab in Treating Patients with Advanced or Metastatic KRAS Wild Type Colorectal Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HCI72561, NCI-2014-01825, NCT02199223
Start Over